US8688188B2
(en)
|
1998-04-30 |
2014-04-01 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6175752B1
(en)
|
1998-04-30 |
2001-01-16 |
Therasense, Inc. |
Analyte monitoring device and methods of use
|
US8346337B2
(en)
|
1998-04-30 |
2013-01-01 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8974386B2
(en)
|
1998-04-30 |
2015-03-10 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6949816B2
(en)
|
2003-04-21 |
2005-09-27 |
Motorola, Inc. |
Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
|
US9066695B2
(en)
|
1998-04-30 |
2015-06-30 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8480580B2
(en)
|
1998-04-30 |
2013-07-09 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US8465425B2
(en)
|
1998-04-30 |
2013-06-18 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods of use
|
US6560471B1
(en)
|
2001-01-02 |
2003-05-06 |
Therasense, Inc. |
Analyte monitoring device and methods of use
|
DE10114178A1
(en)
*
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinc-free and low-zinc insulin preparations with improved stability
|
US7041468B2
(en)
|
2001-04-02 |
2006-05-09 |
Therasense, Inc. |
Blood glucose tracking apparatus and methods
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
PT1412384E
(en)
|
2001-06-28 |
2008-03-28 |
Novo Nordisk As |
Stable formulation of modified glp-1
|
DE10227232A1
(en)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Sour insulin preparations with improved stability
|
US20090035260A1
(en)
*
|
2002-07-29 |
2009-02-05 |
Therapicon Srl |
Enhanced nasal composition of active peptide
|
ITMI20021684A1
(en)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
PHARMACEUTICAL COMPOSITION OF NASAL PEPTIDE
|
EP1578262A4
(en)
|
2002-12-31 |
2007-12-05 |
Therasense Inc |
Continuous glucose monitoring system and methods of use
|
US8771183B2
(en)
|
2004-02-17 |
2014-07-08 |
Abbott Diabetes Care Inc. |
Method and system for providing data communication in continuous glucose monitoring and management system
|
AU2004232858B2
(en)
|
2003-04-23 |
2009-07-09 |
Mannkind Corporation |
Hydraulically actuated pump for long duration medicament administration
|
JP4936884B2
(en)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー/エス |
Stabilized pharmaceutical peptide composition
|
JP2007524592A
(en)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー/エス |
Stabilized pharmaceutical peptide composition
|
US8066639B2
(en)
|
2003-06-10 |
2011-11-29 |
Abbott Diabetes Care Inc. |
Glucose measuring device for use in personal area network
|
RU2421238C2
(en)
|
2003-11-20 |
2011-06-20 |
Ново Нордиск А/С |
Peptide composition containing propylene glycol optimal for manufacturing and application in injection devices
|
ITMI20040235A1
(en)
*
|
2004-02-13 |
2004-05-13 |
Therapicon Srl |
PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
|
WO2006014425A1
(en)
|
2004-07-02 |
2006-02-09 |
Biovalve Technologies, Inc. |
Methods and devices for delivering glp-1 and uses thereof
|
RU2393168C2
(en)
|
2004-07-19 |
2010-06-27 |
Биокон Лимитед |
Insulin-oligomer conjugates, preparations and use thereof
|
US8710181B2
(en)
|
2004-08-31 |
2014-04-29 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
CA2586771A1
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
CN101106979A
(en)
*
|
2005-01-21 |
2008-01-16 |
阿尔扎公司 |
Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
|
US8112240B2
(en)
|
2005-04-29 |
2012-02-07 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing leak detection in data monitoring and management systems
|
JP5235661B2
(en)
*
|
2005-05-25 |
2013-07-10 |
ノボ・ノルデイスク・エー/エス |
Stabilized polypeptide preparation
|
US20090060861A1
(en)
*
|
2005-05-25 |
2009-03-05 |
Novo Nordisk A/S |
Stabilized Polypeptide Formulations
|
WO2007037795A2
(en)
|
2005-08-05 |
2007-04-05 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
US7766829B2
(en)
|
2005-11-04 |
2010-08-03 |
Abbott Diabetes Care Inc. |
Method and system for providing basal profile modification in analyte monitoring and management systems
|
US20070191271A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
EP2982399B1
(en)
|
2006-03-30 |
2017-12-06 |
Valeritas, Inc. |
Multi-cartridge fluid delivery device
|
US8226891B2
(en)
|
2006-03-31 |
2012-07-24 |
Abbott Diabetes Care Inc. |
Analyte monitoring devices and methods therefor
|
US7620438B2
(en)
|
2006-03-31 |
2009-11-17 |
Abbott Diabetes Care Inc. |
Method and system for powering an electronic device
|
US20080071158A1
(en)
|
2006-06-07 |
2008-03-20 |
Abbott Diabetes Care, Inc. |
Analyte monitoring system and method
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8732188B2
(en)
|
2007-02-18 |
2014-05-20 |
Abbott Diabetes Care Inc. |
Method and system for providing contextual based medication dosage determination
|
US8930203B2
(en)
|
2007-02-18 |
2015-01-06 |
Abbott Diabetes Care Inc. |
Multi-function analyte test device and methods therefor
|
US8123686B2
(en)
|
2007-03-01 |
2012-02-28 |
Abbott Diabetes Care Inc. |
Method and apparatus for providing rolling data in communication systems
|
US8456301B2
(en)
|
2007-05-08 |
2013-06-04 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
US8461985B2
(en)
|
2007-05-08 |
2013-06-11 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
US8665091B2
(en)
|
2007-05-08 |
2014-03-04 |
Abbott Diabetes Care Inc. |
Method and device for determining elapsed sensor life
|
US7928850B2
(en)
|
2007-05-08 |
2011-04-19 |
Abbott Diabetes Care Inc. |
Analyte monitoring system and methods
|
EP2203181B1
(en)
|
2007-10-16 |
2018-02-14 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
AU2009212166A1
(en)
|
2008-02-07 |
2009-08-13 |
University Of Washington |
Circumferential aerosol device
|
CN102037008B
(en)
|
2008-03-18 |
2016-08-31 |
诺沃-诺迪斯克有限公司 |
Protease stabilized, acylated insulin analog
|
TWI451876B
(en)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
Pegylated insulin lispro compounds
|
CN109010254A
(en)
|
2008-08-15 |
2018-12-18 |
硬木药品公司 |
It is suitble to the stable solid pharmaceutical preparation of the guanylate cyclase-C receptor agonist polypeptide of oral administration
|
LT2349324T
(en)
|
2008-10-17 |
2017-12-27 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a glp-1 agonist
|
US8103456B2
(en)
|
2009-01-29 |
2012-01-24 |
Abbott Diabetes Care Inc. |
Method and device for early signal attenuation detection using blood glucose measurements
|
US9226701B2
(en)
|
2009-04-28 |
2016-01-05 |
Abbott Diabetes Care Inc. |
Error detection in critical repeating data in a wireless sensor system
|
WO2010138856A1
(en)
|
2009-05-29 |
2010-12-02 |
Abbott Diabetes Care Inc. |
Medical device antenna systems having external antenna configurations
|
JP5669834B2
(en)
*
|
2009-06-26 |
2015-02-18 |
ノボ・ノルデイスク・エー/エス |
Formulation containing insulin, nicotinamide and amino acid
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
WO2011017502A2
(en)
|
2009-08-06 |
2011-02-10 |
Ironwood Pharmaceuticals, Inc. |
Linaclotide-containing formulations for oral administration
|
WO2011026147A1
(en)
|
2009-08-31 |
2011-03-03 |
Abbott Diabetes Care Inc. |
Analyte signal processing device and methods
|
EP2473099A4
(en)
|
2009-08-31 |
2015-01-14 |
Abbott Diabetes Care Inc |
Analyte monitoring system and methods for managing power and noise
|
EP2482720A4
(en)
|
2009-09-29 |
2014-04-23 |
Abbott Diabetes Care Inc |
Method and apparatus for providing notification function in analyte monitoring systems
|
ES2855146T3
(en)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
TWI468171B
(en)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
US20110152820A1
(en)
*
|
2009-12-22 |
2011-06-23 |
Medtronic Minimed, Inc. |
Barrier coatings for fluids contacting medical devices
|
US20160243199A1
(en)
*
|
2015-02-25 |
2016-08-25 |
Dance Biopharm, Inc. |
Liquid insulin formulations and methods relating thereto
|
MX340234B
(en)
|
2010-02-17 |
2016-07-01 |
Ironwood Pharmaceuticals Inc |
Treatments for gastrointestinal disorders.
|
HUE046922T2
(en)
|
2010-08-11 |
2020-03-30 |
Ironwood Pharmaceuticals Inc |
Stable formulations of linaclotide
|
CN103179978A
(en)
|
2010-08-30 |
2013-06-26 |
赛诺菲-安万特德国有限公司 |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
RU2728583C2
(en)
|
2011-03-03 |
2020-07-30 |
Импел Ньюрофарма Инк. |
Device for nasal drug delivery
|
WO2012154859A1
(en)
|
2011-05-09 |
2012-11-15 |
Impel Neuropharma Inc. |
Nozzles for nasal drug delivery
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
PL2776055T3
(en)
|
2011-08-17 |
2017-06-30 |
Ironwood Pharmaceuticals, Inc. |
Treatments for gastrointestinal disorders
|
JP6367115B2
(en)
|
2011-08-29 |
2018-08-01 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Combination medicine used for blood glucose control in patients with type 2 diabetes
|
AR087744A1
(en)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
|
WO2013070794A2
(en)
|
2011-11-07 |
2013-05-16 |
Abbott Diabetes Care Inc. |
Analyte monitoring device and methods
|
WO2013158276A1
(en)
*
|
2012-04-20 |
2013-10-24 |
Children's Hospital Medical Center |
Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
|
US9662445B2
(en)
|
2012-08-30 |
2017-05-30 |
Medtronic Minimed, Inc. |
Regulating entry into a closed-loop operating mode of an insulin infusion system
|
US9878096B2
(en)
|
2012-08-30 |
2018-01-30 |
Medtronic Minimed, Inc. |
Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
|
US10496797B2
(en)
|
2012-08-30 |
2019-12-03 |
Medtronic Minimed, Inc. |
Blood glucose validation for a closed-loop operating mode of an insulin infusion system
|
US9364609B2
(en)
|
2012-08-30 |
2016-06-14 |
Medtronic Minimed, Inc. |
Insulin on board compensation for a closed-loop insulin infusion system
|
US9849239B2
(en)
|
2012-08-30 |
2017-12-26 |
Medtronic Minimed, Inc. |
Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
|
US9623179B2
(en)
|
2012-08-30 |
2017-04-18 |
Medtronic Minimed, Inc. |
Safeguarding techniques for a closed-loop insulin infusion system
|
US10130767B2
(en)
|
2012-08-30 |
2018-11-20 |
Medtronic Minimed, Inc. |
Sensor model supervisor for a closed-loop insulin infusion system
|
US9968306B2
(en)
|
2012-09-17 |
2018-05-15 |
Abbott Diabetes Care Inc. |
Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
|
KR102205512B1
(en)
|
2012-11-13 |
2021-01-20 |
아도시아 |
Quick-acting insulin formulation including a substituted anionic compound
|
WO2014096985A2
(en)
|
2012-12-19 |
2014-06-26 |
Wockhardt Limited |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
AU2013368990B2
(en)
|
2012-12-26 |
2017-05-18 |
Wockhardt Limited |
Pharmaceutical composition
|
US10537692B2
(en)
|
2013-04-28 |
2020-01-21 |
Impel Neuropharma, Inc. |
Medical unit dose container
|
CR20170314A
(en)
|
2014-12-12 |
2017-10-20 |
Sanofi Aventis Deutschland |
FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
|
TWI748945B
(en)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
Treatment type 2 diabetes mellitus patients
|
TW201705975A
(en)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
Treatment of type 2 diabetes mellitus patients
|
EP3341059B1
(en)
|
2015-09-10 |
2022-03-02 |
Impel NeuroPharma Inc. |
In-line nasal delivery device
|
TWI700092B
(en)
|
2016-12-16 |
2020-08-01 |
丹麥商諾佛.儂迪克股份有限公司 |
Insulin containing pharmaceutical compositions
|
KR20200044016A
(en)
|
2017-08-24 |
2020-04-28 |
노보 노르디스크 에이/에스 |
GLP-1 composition and use
|
WO2019104205A1
(en)
|
2017-11-21 |
2019-05-31 |
Impel Neuropharma, Inc. |
Intranasal device with dip tube
|
WO2019104192A1
(en)
|
2017-11-21 |
2019-05-31 |
Impel Neuropharma, Inc. |
Intranasal device with inlet interface
|
US11278492B2
(en)
|
2018-01-05 |
2022-03-22 |
Impel Neuropharma, Inc. |
Intranasal delivery of olanzapine by precision olfactory device
|
JP7317020B2
(en)
|
2018-01-05 |
2023-07-28 |
インペル ファーマシューティカルズ インコーポレイテッド |
Intranasal delivery of dihydroergotamine by a precision olfactory device
|
EP3823607A4
(en)
|
2018-07-19 |
2022-04-06 |
Impel NeuroPharma Inc. |
Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
|
BR112021013244A8
(en)
|
2019-01-03 |
2022-10-18 |
Impel Neuropharma Inc |
NASAL DRUG DELIVERY DEVICE
|
WO2020236658A1
(en)
|
2019-05-17 |
2020-11-26 |
Impel Neuropharma, Inc. |
Single-use nasal delivery device
|
PE20221575A1
(en)
|
2020-02-18 |
2022-10-06 |
Novo Nordisk As |
PHARMACEUTICAL FORMULATIONS
|